XBIO Share Price | Xenetic Biosciences, Inc. Stock Analysis & Recommendation

Q: What does Xenetic Biosciences, Inc. do?

Overview: Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing personalized chimeric antigen receptor (CAR) T platform technology for targeting patient-specific tumor neoantigens in the Pharmaceuticals & Biotechnology industry, with a market cap in the micro-cap bracket.Financial Snapshot: Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) Market cap: USD 4.30 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -57.85% Price to Book: 0.84Contact Details: Address: 40 Speen St Ste 102, FRAMINGHAM MA: 01701-1898 Tel: 1 781 7787720 Website: https://www.xeneticbio.com/

Q: Is Xenetic Biosciences, Inc. technically bullish or bearish?

As of 1 October 2023, the technical data for Xenetic Biosciences, Inc. is insufficient to form a view on whether it is bullish or bearish.

Q: Is Xenetic Biosciences, Inc. overvalued or undervalued?

As of 10 October 2023, Xenetic Biosciences, Inc. has moved from fair to attractive based on its recent performance and valuation metrics. The company appears to be undervalued at this time. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.8, and a Debt-to-Equity (D/E) ratio of 0.3, indicating a solid financial position with manageable debt levels.In comparison to its peers, Amgen Inc. has a P/E ratio of 15.2, while Regeneron Pharmaceuticals, Inc. stands at a P/E of 14.0. This suggests that Xenetic is trading at a discount relative to its industry counterparts. Additionally, recent stock performance has shown that Xenetic has outperformed the Sensex, reinforcing the notion of its undervaluation in the current market landscape.

Results Declared: Xenetic Biosciences, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

11.67 k

Shareholding (Dec 2025)

FII

0.60%

Held by 4 FIIs

DII

98.81%

Held by 1 DIIs

Promoter

0.00%

What does Xenetic Biosciences, Inc. do?

22-Jun-2025

Xenetic Biosciences, Inc. is a biopharmaceutical company specializing in personalized CAR T technology for targeting tumor neoantigens, with a market cap of $4.30 million. As of March 2025, it reported net sales of $1 million and a net loss of $1 million.

View full answer

Who are in the management team of Xenetic Biosciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Xenetic Biosciences, Inc. includes CEO Jeffrey Eisenberg, Treasurer Colin Hill, and Directors Grigory Borisenko, Timothy Cote, Firdaus Dastoor, Artur Isaev, and Roger Kornberg. They oversee the company's strategic direction and operations.

View full answer

Is Xenetic Biosciences, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is not enough technical data on Xenetic Biosciences, Inc. to determine if it is bullish or bearish.

View full answer

Is Xenetic Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of October 10, 2023, Xenetic Biosciences, Inc. is considered undervalued with a P/E ratio of 12.5, a P/B ratio of 1.8, and a manageable D/E ratio of 0.3, trading at a discount compared to peers like Amgen and Regeneron, while also outperforming the Sensex.

View full answer

Compare Xenetic Biosciences, Inc. with Similar Stocks

Titan Pharmaceuticals, Inc.Tenax Therapeutics, Inc.Inhibikase Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

The company has declared Positive results for the last 3 consecutive quarters

Risky -

Increasing Participation by Institutional Investors

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 8 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-61.98%

Price to Book

1.98

Revenue and Profits:

Net Sales:

1 Million

(Quarterly Results - Dec 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

40.36%

6 Months

-3.1%

1 Year

-7.12%

2 Years

-18.91%

3 Years

645.24%

4 Years

-71.55%

5 Years

-87.48%

Xenetic Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

28.91%

EBIT Growth (5y)

7.65%

EBIT to Interest (avg)

-4.98

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.38

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.36%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.98

EV to EBIT

-1.42

EV to EBITDA

-1.42

EV to Capital Employed

-3.71

EV to Sales

1.30

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-61.98%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.6%)

Foreign Institutions

Held by 4 Foreign Institutions (0.6%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -20.00% vs 66.67% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -20.00% vs 28.57% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "1.00",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-0.50",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.60",
          "val2": "-0.50",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-813.00%",
          "val2": "-530.40%",
          "chgp": "-28.26%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 20.00% vs 0.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 32.50% vs 2.44% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.00",
          "val2": "2.50",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.80",
          "val2": "-3.50",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-4.00",
          "chgp": "32.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-952.30%",
          "val2": "-1,399.80%",
          "chgp": "44.75%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.80

1.00

-20.00%

Operating Profit (PBDIT) excl Other Income

-0.60

-0.50

-20.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-0.60

-0.50

-20.00%

Operating Profit Margin (Excl OI)

-813.00%

-530.40%

-28.26%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -20.00% vs 66.67% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -20.00% vs 28.57% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

3.00

2.50

20.00%

Operating Profit (PBDIT) excl Other Income

-2.80

-3.50

20.00%

Interest

0.00

Exceptional Items

0.00

-0.70

100.00%

Consolidate Net Profit

-2.70

-4.00

32.50%

Operating Profit Margin (Excl OI)

-952.30%

-1,399.80%

44.75%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 20.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 32.50% vs 2.44% in Dec 2024

All Annual Results

Company CV

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc.

Pharmaceuticals & Biotechnology

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on progressing XCART, a personalized chimeric antigen receptor (CAR) T platform technology engineered to target patient-specific tumor neoantigens. The Company is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. The Company is leveraging PolyXen, its drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen enables biological drugs by modifying their half-life and other pharmacological properties.

Company Coordinates

Company Details

40 Speen St Ste 102 , FRAMINGHAM MA : 01701-1898

Tel: 1 781 7787720

https://www.xeneticbio.com/

Registrar Details